Meritage Portfolio Management Fate Therapeutics Inc Call Options Transaction History
Meritage Portfolio Management
- $1.55 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding FATE
# of Institutions
148Shares Held
94.9MCall Options Held
46.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.1 Million1.07% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.24 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$7.33 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$4.03 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $91.2M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...